Effect of 18F-FDG PET/CT in esophageal cancer patients with early recurrence lesions

In the initial staging of esophageal cancer, preoperative PET scan may be useful in detecting additional cases of metastatic disease before costly and toxic definitive therapy.

Currently, 18F-FDG PET and PET/CT also seem to be the best available tools for neoadjuvant therapy response assessment in esophageal cancer. However, the utility and limitation of 18F-FDG PET/CT in patients with esophageal cancer treated by surgical resection and post operation radiation is not clear.

A research article to be published on April 21, 2009 in the World Journal of Gastroenterology addresses this question. The research carried out by Professor Wu from Minnan PET Center and department of nuclear medicine aimed to evaluate the clinical usefulness of 18F-FDG PET/CT in the restaging of esophageal cancer after surgical resection and radiotherapy. Their initial results suggested 18F-FDG PET/CT is might be a highly sensitive diagnosis and accurate whole-body staging of asymptomatic and symptomatic recurrent esophageal cancer. 18F-FDG PET/CT guided- salvage treatment to the early recurrence lesion might improve patient survival in a considerable proportion of patients.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MRI-guided SBRT reduces side effects in prostate cancer treatment